Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Business
Corp. News
Latest Headlines
Biotech
Investors
Stock Alerts
IPOs
M&A
Top Stories
Breaking News
Earnings
Canadian
UK
Wallstreet Events
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Crypto
Cryptocurrency
Blockchain
Markets
Market News
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
US
World
White House
Elections
General News
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health News
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment News
Top Stories
Music News
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium
Intelligent Investor
Biotech Investor
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Daiichi Sankyo Company Limited (DSKYF)
AstraZeneca, Daiichi Sankyo Get Positive CHMP Opinion For Enhertu In HER2-Positive Solid Tumours
5/26/2026 2:43:06 AM
FDA Approves AstraZeneca And Daiichi's Datroway For Treating Metastatic Breast Cancer
5/22/2026 11:53:13 AM
AstraZeneca, Daiichi Sankyo's Datroway Gets Approval In US For Treatment Of Breast Cancer
5/22/2026 10:35:34 AM
Daiichi Sankyo & AstraZeneca Win U.S. Approval For Datroway In Metastatic Triple-Negative Breast Cancer
5/22/2026 9:45:52 AM
AstraZeneca: FDA Approves Enhertu For Two New Indications
5/18/2026 2:39:55 AM
AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings
5/17/2026 11:49:36 AM
Daiichi Sankyo Unveils Five-year Plan Targeting 2.3 Tln Yen Oncology Revenue By 2030
5/11/2026 4:19:09 AM
Daiichi Sankyo Plans To Deliver More Than 2.3 Tln Yen In Oncology Revenue By 2030
5/11/2026 3:49:31 AM
Daiichi Sankyo Expects Annual Results To Improve On Higher Enhertu, Datroway Sales
5/11/2026 3:43:22 AM
Daiichi Sankyo Earnings Fall; Guides FY27
5/11/2026 3:04:27 AM
Daiichi Sankyo Company Limited Profit Retreats In Full Year
5/11/2026 2:45:12 AM
Daiichi Sankyo FY Basic EPS 140.44 Yen Vs 155.96 Yen Last Year
5/11/2026 2:39:55 AM
Wayfinder Biosciences Advances Collaboration With Daiichi Sankyo On Key Neurodegeneration Target To Second Phase
4/15/2026 9:23:51 AM
Daiichi Sankyo: FDA Grants Priority Review For Ifinatamab Deruxtecan
4/13/2026 7:28:02 AM
Daiichi Sankyo, Merck: FDA Grants Priority Review For Ifinatamab Deruxtecan For Treatment Of Adult Patients With ES-SCLC
4/13/2026 7:06:18 AM
Nuvation Bio Acquires Japan Rights For Safusidenib; Now Owns Global Clinical Development Program
4/1/2026 8:14:27 AM
Nuvation Bio Secures Global Rights To Safusidenib With Japan Expansion
4/1/2026 8:06:17 AM
Tempus AI Enters Collaboration With Daiichi Sankyo
3/25/2026 8:52:37 AM
Tempus AI Enters Strategic Collaboration With Daiichi Sankyo To Advance Oncology ADC Program
3/25/2026 8:38:29 AM
Older Articles